New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
10:00 EDTAEGR, RPTP, SWKS, MDVN, FUR, WGP, LLNW, CERN, STAG, IDRA, AKAM, QSII, GWAYOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Akamai (AKAM) initiated with a Neutral at Macquarie... Cerner (CERN) initiated with an Overweight at JPMorgan... Greenway Medical (GWAY) initiated with an Overweight at JPMorgan... Idera Pharmaceuticals (IDRA) initiated with an Overweight at Piper Jaffray... Limelight Networks (LLNW) initiated with a Neutral at Macquarie... Quality Systems (QSII) initiated with an Underweight at JPMorgan... STAG Industrial (STAG) initiated with a Market Perform at Wells Fargo... Western Gas Equity (WGP) initiated with a Buy at Citigroup... Winthrop Realty (FUR) initiated with a Market Perform at JMP Securities... Skyworks (SWKS) initiated with a Buy at Longbow... Aegerion (AEGR) initiated with a Buy at Janney Capital... Medivation (MDVN) initiated with a Buy at Janney Capital... Raptor Pharmaceuticals (RPTP) initiated with a Buy at Janney Capital.
News For AKAM;CERN;GWAY;IDRA;LLNW;QSII;STAG;WGP;FUR;SWKS;AEGR;MDVN;RPTP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 19, 2015
08:13 EDTFURWinthrop Realty announces sale of assets held by MSREF venture
Subscribe for More Information
07:48 EDTAKAMAkamai downgraded on valuation, comps at Oppenheimer
Subscribe for More Information
07:25 EDTAKAMAkamai price target raised to $88 from $79 at UBS
Subscribe for More Information
06:38 EDTAKAMAkamai downgraded to Perform from Outperform at Oppenheimer
May 18, 2015
16:25 EDTWGPWestern Gas Equity initiated with a Hold at Deutsche Bank
Subscribe for More Information
12:46 EDTSWKSSkyworks expands portfolio of RF switches for Internet of Things
Subscribe for More Information
08:52 EDTIDRAIdera Pharmaceuticals provides development update on IMO-9200
Idera Pharmaceuticals announced the achievement of key development milestones for its product candidate IMO-9200, an antagonist of Toll-like receptors, or TLRs, 7, 8 and 9. Specifically, the company reported top-line data from a Phase 1 clinical trial of IMO-9200 in healthy subjects and announced the presentation of new preclinical data for IMO-9200 in models of inflammatory bowel disease, or IBD, at the 2015 Digestive Disease Week Conference, or DDW, in Washington, DC. In the placebo-controlled Phase 1 clinical trial in 30 healthy subjects, IMO-9200 was administered by subcutaneous injection at escalating single-dose levels of 0.1, 0.3, and 0.5 mg/kg. In the multiple dose cohort, a dose of 0.5 mg/kg/week for four weeks was also evaluated. All dose regimens were well tolerated, with no serious adverse events related to IMO-9200 treatment reported. There were no patterns of laboratory or other safety parameters suggestive of any related adverse treatment effect. Additionally, new preclinical data for IMO-9200 were presented on Saturday, May 16 at the 2015 Digestive Disease Week Conference. The poster presentation, entitled "Targeting Innate Immune Receptors to Treat Inflammatory Bowel Disease: Activity of Oral IMO-9200, an Antagonist of TLRs 7, 8, and 9 in Mouse Models of Colitis," provided results from two mouse models of colitis. These results demonstrated the potential of orally dosed IMO-9200 as a treatment for inflammatory bowel disease, which includes Crohn's disease, or CD, and ulcerative colitis.
07:22 EDTCERNUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 18 at 8 am; not all company presentations may be webcasted. Webcast Link
May 17, 2015
12:53 EDTMDVNMedivation, Astellas report enzalutamide study met primary endpoint
Subscribe for More Information
May 15, 2015
07:35 EDTMDVNMedivation price target raised to $148 from $128 at Leerink
Subscribe for More Information
May 14, 2015
17:03 EDTAEGRAegerion CFO resigns, David Aubuchon named acting CFO
Subscribe for More Information
07:07 EDTMDVNMedivation to present data in TNBC at ASCO
Medivation announced that the following abstract will be presented during an oral presentation at the 2015 American Society of Clinical Oncology, or ASCO, Annual Meeting on June 1, in Chicago: Results from a phase 2 study of enzalutamide, an androgen receptor, or AR, inhibitor, in advanced AR+ triple-negative breast cancer, or TNBC.
May 13, 2015
15:32 EDTLLNW, AKAMLimelight Networks says favorable ruling received in Akamai patent suit
Subscribe for More Information
14:10 EDTAKAM, LLNWCourt says Limelight Networks did not infringe on Akamai patent, Bloomberg says
Subscribe for More Information
11:12 EDTWGPEnergy MLPs weak despite Williams deal for Williams Partners
Subscribe for More Information
10:28 EDTLLNW, AKAMCourt says Limelight Networks did not infringe on Akamai patent, Bloomberg says
Akamai was looking to reinstate $45.5M patent verdict, added Bloomberg.
09:44 EDTWGPMLPs that could trade up on Williams, Williams Partners news, says Credit Suisse
Credit Suisse said Plains GP Holdings (PAGP), Targa Resources (TRGP), NuStar (NSH), Western Gas Equity (WGP) could trade up on the Williams (WMB)/Williams Partners (WPZ) merger news.
07:32 EDTAKAMCLSA to hold a conference
Subscribe for More Information
May 12, 2015
08:31 EDTAKAMAkamai management to meet with JMP Securities
Meetings to be held in Denver on May 13 and in Los Angeles on May 14 hosted by JMP Securities.
May 11, 2015
07:38 EDTIDRAIdera Pharmaceuticals reports Q1 EPS (12c), consensus (11c)
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use